High-Dose cocktail shows promise against new myeloma
NCT ID NCT02937571
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 29 people newly diagnosed with multiple myeloma. The goal was to find the safest high dose of carfilzomib and see how well it clears cancer cells from the body. Researchers measured side effects and checked for minimal residual disease (tiny amounts of leftover cancer).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this could lead to a more effective initial treatment for multiple myeloma, potentially achieving deeper remission with manageable side effects.
What could go wrong
This is an early-phase study with only 29 participants, so results may not apply to all patients. The high-dose carfilzomib may cause significant side effects, and long-term benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States